Thermo Fisher Scientific (California, USA) has collaborated with Immunodiagnostik (Bensheim, Germany) to develop novel assays for the commercial qualitative and quantitative analysis of protein and peptide biomarkers in disease diagnosis
Thermo Fisher Scientific (California, USA) has collaborated with Immunodiagnostik (Bensheim, Germany) to develop novel assays for the commercial qualitative and quantitative analysis of protein and peptide biomarkers in disease diagnosis.
The collaboration seeks to further biomarker research, by combining the antibody-based detection technology developed by Immunodiagnostik with the liquid–chromatrography tandem mass spectrometry (LC–MS–MS) analytical technology from Thermo Scientific. The companies hope to enable the development of assays specifically for the diagnosis of cardiovascular disease and bone metabolism disorders. Furthermore, Immunodiagnostik will utilize its academic and clinical network connections to allow the validation of developed assays.
“We are impressed with Immundiagnostik’s antibody expertise, and are confident that the immunoaffinity-purification of proteins will take quantitative LC–MS–MS protein analysis to the next level,” said Jeff Zonderman, Thermo Fisher director of clinical and toxicology LC–MS.
For more information please visit:ref=http://www.thermofisher.com>www.thermofisher.com
Targeted Blood Lipidomics of Colorectal Cancer: An HTC-18 Interview with Jef Focant
July 26th 2024At HTC-18 in Leuven, Executive Editor of LCGC International, Alasdair Matheson, spoke to Jef Focant from the University of Liege about his talk entitled, “Targeted Blood Lipidomics of Colorectal Cancer."
Carol Robinson Awarded 2024 Lifetime Achievement European Inventor Award
July 24th 2024Carol Robinson of the University of Oxford has received the European Inventor Award 2024 for Lifetime Achievement from the European Patent Office for her work bringing mass spectrometry to structural biology.